SOAT1 and ovarian carcinoma: While ruxolitinib is an exciting small molecule inhibitor, there are limited studies using gene therapy approaches such as siRNA, which may enhance silencing of JAK or STAT proteins in ovarian cancer and should be explored in future studies.